AGTT, the OTC-listed Angstrom Technologies, is a stock where the data itself is the story — and the story is one of near-total illiquidity and stale records.
The share price closed at $0.07 on April 27, a drop of 12.5% on both the day and the week. That move sits against a 17% gain over the prior month, a pattern typical of micro-cap names where thin volume turns routine session moves into outsized percentage swings. With a market capitalisation of just $2.4 million, the company sits deep in micro-cap territory, below even the small-cap threshold.
The positioning picture is largely meaningless to interpret in conventional terms. The most recent short interest data on record dates to January 2020 — more than six years ago. That reading put shares short at just 66, a number so small it reflects none of the usual lending-market dynamics worth discussing. Similarly, cost-to-borrow figures carry the same 2020 date stamp and show a negative value, which is a technical artefact of data age rather than a market signal. No float percentage, no availability reading, and no borrow cost from the current period are available. Analysts have no coverage. Institutional holders, earnings history, options data, and valuation multiples are all absent or too stale to cite.
What remains is a security trading on the OTC Pink Sheets with a sub-$3 million cap, no analyst coverage, no news flow, and no recent short interest data. For traders and investors, the absence of data is itself instructive: this is a name where normal market infrastructure — research, borrow markets, institutional participation — does not exist.
The one metric worth watching is whether any volume accumulation or news event emerges to explain the April price action. Without that, the week's 12.5% decline is noise in an otherwise quiet name.
See the live data behind this article on ORTEX.
Open AGTT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
